HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Breast Cancer Update
00:00
Managing double‑mutant (ESR1 + PIK3CA/AKT) disease
Discussion of using AKT/PI3K inhibitors, capivasertib preference over alpelisib, and strategy based on symptoms.
Play episode from 39:04
Transcript
